id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-0779-0022,FDA,FDA-2014-D-0779,"Letter from the National Home Infusion Association re Comment from Barbara Petroff, MS, RPh, FASHP",Supporting & Related Material,Background Material,2014-09-26T04:00:00Z,2014,9,,,2014-09-26T19:38:25Z,,0,0,090000648187d26d
FDA-2014-D-0779-0001,FDA,FDA-2014-D-0779,"Draft Guidance for Industry on Current Good Manufacturing Practice—Interim Guidance for Human Drug Compounding Outsourcing Facilities
Under the Federal Food, Drug and Cosmetic Act; Availability",Notice,Notice of Availability,2014-07-02T04:00:00Z,2014,7,2014-07-02T04:00:00Z,2014-09-03T03:59:59Z,2014-09-12T01:04:43Z,2014-15370,0,0,0900006481786f3c
FDA-2014-D-0779-0002,FDA,FDA-2014-D-0779,"Draft Guidance for Industry on Current Good Manufacturing Practice—Interim Guidance for Human Drug Compounding Outsourcing Facilities
Under the Federal Food, Drug and Cosmetic Act",Other,Guidance,2014-07-02T04:00:00Z,2014,7,2014-07-02T04:00:00Z,,2019-08-20T19:39:31Z,,0,0,0900006481787d75